GREENWICH LIFESCIENCES, INC. Preferred Stock, Shares Authorized
GREENWICH LIFESCIENCES, INC. (GLSI) had Preferred Stock, Shares Authorized of 10.00 million shares as of 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Balance Sheet › Equity › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockSharesAuthorized · last filed 2021-03-31
- 2020-12-31: Preferred Stock, Shares Authorized 10.00M shares.
- 2020-09-30: Preferred Stock, Shares Authorized 10.00M shares.
- 2019-12-31: Preferred Stock, Shares Authorized 10.00M shares.
| Period end | Preferred Stock, Shares Authorized |
|---|---|
| 2020-12-31 | 10.00M shares 10-K · filed 2021-03-31 |
| 2020-09-30 | 10.00M shares 10-Q · filed 2020-11-16 |
| 2019-12-31 | 10.00M shares 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |